medigraphic.com
ISSN 1025-0255 (Electronic)

2013, Number 5

<< Back Next >>

AMC 2013; 17 (5)

Clinical progress of patients w ith diabetic foot ulcer treated w ith HeberprotP®

Alvarez CAR, Alonso CL, Yera AI, García MAJ

Language: Spanish
References: 20
Page: 544-556
PDF size: 296.63 Kb.


ABSTRACT

Background: HeberprotP®, prescribed for the treatment of diabetic foot ulcer, contributes to the reestablishment of the granulation tissue, being favorable to the cicatrisation process.
Objective: to characterize the clinical progress of patients with diabetic foot ulcer treated with HeberprotP®.
Method: an observational, prospective, multicentric study of monitoring of the postmarketing of HeberprotP® was conducted between June, 2007 and March, 2010 in Havana city.
Results: the 53.1 % of the patients were female and the average age was 62.66 ± 11.758 years old. High blood pressure was the most frequent pathology in the patients with diabetic foot ulcer, being present in the 65 % of them. In the 75.2 % of the patients treated with HeberprotP®, a complete granulation was observed. Diabetic foot ulcers were more frequent in the 66.1 % of the type II diabetic patients; the ulcers were on stage 3 and 4 of Wagner (39.5 % and 27.7 %, respectively). The 81.9 % of the patients used the dose of 75 µg.
Conclusions: in around the three fourths of the medicated patients, a complete granulation was achieved; there was an association between it and the type of diabetes mellitus.


REFERENCES

  1. Berlanga Acosta J, Savigne W, Valdez C, Franco N, Alba JS, del Rio A, et al. Epidermal growth factor intralesional infiltrations can prevent amputation inpatient with advanced diabetic foot wounds. Int Wound J. 2006;3(3):2329.

  2. FernándezMontequín JI, InfanteCristiá E, ValenzuelaSilva C, FrancoPérez N, SavigneGutierrez W, ArtazaSanz H, et al. Intralesional injections of CitoprotP_ (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. Int Wound J. 2007;4:33343.

  3. Colectivo de autores. Experiencia Cubana en la extensión del uso del Heberprot P. En: FernándezMontequín J, Berlanga Acosta J, López Saura PA, López Mola E, Herrera ML, Yera Alós I, et al. Infiltración del HeberprotP. La Habana: Editorial Elfos Scientiae; 2009. p. 1006.

  4. American Diabetes Association (ADA). Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008;31(1):5560.

  5. Wagner FW. The dysvascular foot a system for diagnosis and treatment. J Foot Ankle Surg. 1981;2:64122.

  6. Llanes Barrios JA, Fernández Montequín JI, Seuc AH, Chirino Carreño N, Hernández Rivero MJ. Caracterización del pie diabético y algunos de sus factores de riesgo. Rev Cubana Ang Cir Vasc. 2010;13(2):108.

  7. Hernández Rivero MJ, Llanes Barrios JA, Acosta Lapera DS. HeberprotP, una terapia eficaz en la prevención de la amputación en el pie diabético. Rev Cubana Ang Cir Vasc. 2009;10(1):311.

  8. García García Y, del Olmo Pimentel D, Valor IZ, Barnés Domínguez JA, Valdés Pérez C. Caracterización clínica de pacientes hospitalizados con una primera amputación de miembros inferiores por pie diabético. Rev Cubana Ang Cir Vasc. 2012;13(2):8.

  9. González Acosta S, Calaña GonzálezPosada B, Marrero Rodríguez I, López Fernández R. Evolución clínica del tratamiento en el pie diabético con HeberprotP o con el método convencional. Rev Cubana Ang Cir Vasc. 2011;11(2):817.

  10. García Herrera AL, Fernández Montequín J. Generalidades del pie diabético. En: García Herrera AL, Fernández Montequín J, Rodríguez FR, editores. El pie diabético. 1ra ed. Madrid: Elsevier; 2004. 127.

  11. FernándezMontequín JI, Betancourt BY, LeyvaGonzález G, López Mola E, GalánNaranjo K, RamírezNavas M, et al. Intralesional administration of epidermal growth factorbased formulation (HeberprotP) in chronic diabetic foot ulcer: treatment up to complete wound closure. Int Wound J. 2009;6(1):6772.

  12. Franco Pérez N, Valdés Pérez C, Llanes Barrios JA, Reynaldo Concepción D, Pérez Leonard D. Las amputaciones de dedos abiertas y cerradas: su evolución en el pie diabético. Rev Cubana Ang Cir Vasc. 2010;11(1):1223.

  13. Ministerio de Salud Pública. Anuario Estadístico de Salud. La Habana: Dirección Nacional de Registros Médicos; 2011.

  14. Guzmán Cayado M, Barreto Cruz T, Casanueva Cabeza MF, Pérez Chi JC. Algunos factores clínicos de riesgo de amputación en un grupo de diabéticos del municipio Artemisa. Rev Cubana Invest Bioméd. 2006;25(1):417.

  15. Llanes Barrios JA, Puentes Madera I, Figueredo DM, Rubio Medina Y, Valdés Pérez C. Caracterización de las afecciones vasculares en pacientes diabéticos del municipio de Jaruco. Rev Cubana Ang Cir Vasc. 2011;12(1):921.

  16. FernándezMontequín JI, ValenzuelaSilva CM, Díaz OG, Savigne W, SanchoSoutelo N, RiveroFernández F, et al. Cuban Diabetic Foot Study Group. Intralesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebocontrolled, doubleblind study. Int Wound J. 2009 Dec;6(6):43243.

  17. Papanas N, Maltezos E. Growth Factors in the Treatment of Diabetic Foot Ulcers: New Technologies, Any Promises? Int Wound J. 2007;6:3753.

  18. Hardikar JV. Efficacy of recombinant human plateletderived growth factor (rhPDGF) based gel in diabetic foot ulcers: a randomized, multicenter, doubleblind, placebocontrolled study in India. Int Wound J. 2005;17(6):14152.

  19. Cavorsi J, Vicari F, Wirthlin DJ, Ennis W, Kirsner R, O'Connell SM, et al. Bestpractice algorithms for the use of a bilayered living cell therapy (Apligraf) in the treatment of lowerextremity ulcers. Int Wound J. 2006;14(2):1029.

  20. Berlanga Acosta J, Lodos J, Reyes O, Infante JF, Caballero E, LópezSaura P. Epidermal growth factor stimulated reepithelialization in pigs. The possible role ofacutewound proteases. Rev Biotec Aplic 1998;15(1):837.




2020     |     www.medigraphic.com